CLAIMS

1. A formulation comprising an anionic or polymeric surfactant, and a GLP-1-like peptide, provided that the surfactant is not sodium tauro-24,25-dihydrofusidate.

2. The formulation of **Claim 1** wherein the surfactant is selected from the group consisting of DSS (docusate sodium, CAS Registry Number [577-11-7]), docusate calcium [CAS number 128-49-4], docusate potassium [CAS number 7491-09-0], sodium dodecyl sulfate, sodium lauryl sulfate, sodium caprylate, sodium cholate, sodium deoxycholate, sodium taurocholate, and sodium glycocholate.

3. The formulation of **Claim 1**, wherein the surfactant is a polymeric (Tween®-40, Tween®-80, or Brij-35®) surfactant.

4. The formulation of **Claim 1**, wherein the GLP-1-like molecule has the amino acid sequence of SEQ ID NO:1; SEQ ID NO:4; or SEQ ID NO:5 or pharmaceutically acceptable salts thereof.

5. The formulation of **Claim 1**, wherein the GLP-1-like peptide is defined by the formula **R_1-SEQ ID NO:2-R_2**, or pharmaceutically acceptable salts thereof, wherein R_1 is selected from the group consisting of L-histidine, D-histidine, desamino-histidine, 2-amino-histidine, β-hydroxy-histidine, homohistidine, alpha-fluoromethyl-histidine, and alpha-methyl-histidine, and R_2 is selected from the group consisting of Gly-OH or NH_2; or

BEST AVAILABLE COPY

the GLP-1-like peptide is defined by the formula R_1-SEQ ID NO:3-R_2 or pharmaceutically acceptable salts thereof,

wherein R_1 is selected from the group consisting of 4-imidazopropionyl, 4-imidazoacetyl, or 4-imidazo-α, α dimethyl-acetyl; and R_2 is selected from the group consisting of Gly-OH or NH_2.

6. The formulation of Claim 1, further comprising an isotonicity agent.

7. The formulation of Claim 6, wherein the isotonicity agent is glycerin.

8. The formulation of Claim 6, wherein the isotonicity agent is sodium chloride.

9. The formulation of Claim 1, further comprising a preservative.

10. The formulation of Claim 9, wherein the preservative is selected from the group consisting of m-cresol, phenol, methylparaben, and benzyl alcohol.

11. A method of treating a person having a condition for which administration of GLP-1 is indicated, said method comprising administering a pharmacologically effective amount of the formulation of Claim 1 to the person.

12. A method of treating a person having a condition for which administration of GLP-1 is indicated, said method comprising administering a pharmacologically effective amount of the formulation of Claim 2 to the person.

BEST AVAILABLE COPY

13. A method of treating a person having a condition for which administration of GLP-1 is indicated, said method comprising administering a pharmacologically effective amount of the formulation of **Claim 3** to the person.

14. A method of treating a person having a condition for which administration of GLP-1 is indicated, said method comprising administering a pharmacologically effective amount of the formulation of **Claim 4** to the person.

15. A method of treating a person having a condition for which administration of GLP-1 is indicated, said method comprising administering a pharmacologically effective amount of the formulation of **Claim 5** to the person.

16. A method of treating a person having a condition for which administration of GLP-1 is indicated, said method comprising administering a pharmacologically effective amount of the formulation of **Claim 6** to the person.

17. A method of treating a person having a condition for which administration of GLP-1 is indicated, said method comprising administering a pharmacologically effective amount of the formulation of **Claim 7** to the person.

18. A method of treating a person having a condition for which administration of GLP-1 is indicated, said method comprising administering a pharmacologically effective amount of the formulation of **Claim 8** to the person.

19. A method of treating a person having a condition for which administration of GLP-1 is indicated, said method comprising administering a pharmacologically effective amount of the formulation of **Claim 9** to the person.

BEST AVAILABLE COPY

20. A method of treating a person having a condition for which administration of GLP-1 is indicated, said method comprising administering a pharmacologically effective amount of the formulation of **Claim 10** to the person.

21. The method of **Claim 11**, wherein the condition is diabetes.

22. The method of **Claim 11**, wherein the condition is selected from the group consisting of obesity, myocardial infarction, catabolic states, and stroke.

23. The method of any one of **Claim 11** wherein the administration is oral.

Add A2

BEST AVAILABLE COPY